{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:21:28Z","timestamp":1787718088311,"version":"build-2784847793"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Within the last several decades, great strides are being made in both the diagnosis and treatment of cardiac amyloidosis, yet the condition itself has been a severely under-recognized cause of heart failure for centuries. For much of medical history, the accumulation of these insoluble fibril deposits was an enigmatic finding, observed primarily post-mortem in patients suffering from chronic inflammatory conditions. This review traces the fascinating evolution of amyloidosis: from its origins as a botanical term mistakenly applied to human pathology, through the serendipitous discoveries of histological stains like Congo red, to the molecular triumphs that identified the specific precursor proteins driving the AL, AA, and ATTR subtypes. By understanding the historical roadblocks and breakthroughs, we can better appreciate the modern diagnostic imaging and targeted therapies that are finally bringing this complex disease out of the shadows.<\/jats:p>","DOI":"10.1007\/s10741-026-10666-8","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:08:44Z","timestamp":1787717324000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The long road to recognition: a historical review of amyloidosis from early pathology to disease-modifying therapy"],"prefix":"10.1007","volume":"31","author":[{"given":"Lauren N.","family":"Halverson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8210-6401","authenticated-orcid":false,"given":"Brett W.","family":"Sperry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"issue":"3","key":"10666_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1046\/j.1365-2141.2001.02999.x","volume":"114","author":"RA Kyle","year":"2001","unstructured":"Kyle RA (2001) Amyloidosis: a convoluted story. Br J Haematol 114(3):529\u2013538. https:\/\/doi.org\/10.1046\/j.1365-2141.2001.02999.x","journal-title":"Br J Haematol"},{"key":"10666_CR2","doi-asserted-by":"publisher","unstructured":"Tanskanen M (2013) Amyloid \u2014 Historical Aspects. Amyloidosis. IntechOpen. doi:https:\/\/doi.org\/10.5772\/53423","DOI":"10.5772\/53423"},{"issue":"2","key":"10666_CR3","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/BF00495677","volume":"49","author":"K Aterman","year":"1976","unstructured":"Aterman K (1976) A historical note on the iodine-sulphuric acid reaction of amyloid. Histochemistry 49(2):131\u2013143. https:\/\/doi.org\/10.1007\/BF00495677","journal-title":"Histochemistry"},{"issue":"1","key":"10666_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/BF01930815","volume":"6","author":"R Virchow","year":"1854","unstructured":"Virchow R (1854) Ueber eine im Gehirn und R\u00fcckenmark des Menschen aufgefundene Substanz mit der chemischen Reaction der Cellulose. Arch Pathol Anat Physiol Klin Med 6(1):135\u2013138. https:\/\/doi.org\/10.1007\/BF01930815","journal-title":"Arch Pathol Anat Physiol Klin Med"},{"issue":"1","key":"10666_CR5","first-page":"50","volume":"16","author":"N Friedreich","year":"1869","unstructured":"Friedreich N, Kekul\u00e9 A (1869) Zur amyloidfrage. Arch F\u00fcr Pathol Anat Physiol F\u00fcr Klin Med 16(1):50\u201365","journal-title":"Arch F\u00fcr Pathol Anat Physiol F\u00fcr Klin Med"},{"issue":"5","key":"10666_CR6","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1136\/hrt.27.5.711","volume":"27","author":"A Pomerance","year":"1965","unstructured":"Pomerance A (1965) Senile cardiac amyloidosis. Br Heart J 27(5):711\u2013718. https:\/\/doi.org\/10.1136\/hrt.27.5.711","journal-title":"Br Heart J"},{"issue":"10","key":"10666_CR7","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","volume":"68","author":"M Grogan","year":"2016","unstructured":"Grogan M, Scott CG, Kyle RA et al (2016) Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol 68(10):1014\u20131020. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.033","journal-title":"J Am Coll Cardiol"},{"key":"10666_CR8","doi-asserted-by":"publisher","unstructured":"Steensma DP (2001) Congo Red. Published online Febr 1. https:\/\/doi.org\/10.5858\/2001-125-0250-CR","DOI":"10.5858\/2001-125-0250-CR"},{"issue":"4","key":"10666_CR9","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/iep.12330","volume":"100","author":"AJ Howie","year":"2019","unstructured":"Howie AJ (2019) Origins of a pervasive, erroneous idea: The green birefringence of Congo red-stained amyloid. Int J Exp Pathol 100(4):208\u2013221. https:\/\/doi.org\/10.1111\/iep.12330","journal-title":"Int J Exp Pathol"},{"key":"10666_CR10","first-page":"510","volume":"116","author":"A Magnus-Levy","year":"1931","unstructured":"Magnus-Levy A (1931) Bence-Jones-Eiweiss und Amyloid. Z Klin Med 116:510\u2013531","journal-title":"Z Klin Med"},{"key":"10666_CR11","doi-asserted-by":"publisher","unstructured":"Multiple Myelome (XII) - MAGNUS-LEVY\u2009\u2013\u20091938 - Acta Medica Scandinavica - Wiley Online Library. Accessed April 2 (2026) https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1111\/j.0954-6820.1938.tb17113.x","DOI":"10.1111\/j.0954-6820.1938.tb17113.x"},{"issue":"3","key":"10666_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/BF02593362","volume":"306","author":"K Apitz","year":"1940","unstructured":"Apitz K (1940) Die Paraproteinosen. Virchows Arch F\u00fcr Pathol Anat Physiol F\u00fcr Klin Med 306(3):631\u2013699. https:\/\/doi.org\/10.1007\/BF02593362","journal-title":"Virchows Arch F\u00fcr Pathol Anat Physiol F\u00fcr Klin Med"},{"issue":"11","key":"10666_CR13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1177\/16.11.673","volume":"16","author":"ED EANES","year":"1968","unstructured":"EANES ED, X-RAY DIFFRACTION STUDIES ON GLENNERGG, AMYLOID FILAMENTS (1968) J Histochem Cytochem 16(11):673\u2013677. https:\/\/doi.org\/10.1177\/16.11.673","journal-title":"J Histochem Cytochem"},{"issue":"3988","key":"10666_CR14","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1126\/science.172.3988.1150","volume":"172","author":"GG Glenner","year":"1971","unstructured":"Glenner GG, Terry W, Harada M, Isersky C, Page D (1971) Amyloid Fibril Proteins: Proof of Homology with Immunoglobulin Light Chains by Sequence Analyses. Science 172(3988):1150\u20131151. https:\/\/doi.org\/10.1126\/science.172.3988.1150","journal-title":"Science"},{"issue":"4010","key":"10666_CR15","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1126\/science.174.4010.712","volume":"174","author":"GG Glenner","year":"1971","unstructured":"Glenner GG, Ein D, Eanes ED, Bladen HA, Terry W, Page DL (1971) Creation of Amyloid Fibrils from Bence Jones Proteins in vitro. Science 174(4010):712\u2013714. https:\/\/doi.org\/10.1126\/science.174.4010.712","journal-title":"Science"},{"issue":"4","key":"10666_CR16","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1172\/JCI107642","volume":"53","author":"G Husby","year":"1974","unstructured":"Husby G, Natvig JB (1974) A Serum Component Related to Nonimmunoglobulin Amyloid Protein AS, a Possible Precursor of the Fibrils. J Clin Invest 53(4):1054\u20131061. https:\/\/doi.org\/10.1172\/JCI107642","journal-title":"J Clin Invest"},{"issue":"2","key":"10666_CR17","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1084\/jem.138.2.373","volume":"138","author":"M Levin","year":"1973","unstructured":"Levin M, Pras M, Franklin EC, IMMUNOLOGIC STUDIES OF THE MAJOR NONIMMUNOGLOBULIN (1973) PROTEIN OF AMYLOID. J Exp Med 138(2):373\u2013380. https:\/\/doi.org\/10.1084\/jem.138.2.373","journal-title":"J Exp Med"},{"issue":"3","key":"10666_CR18","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/brain\/75.3.408","volume":"75","author":"A PECULIAR FORM OF PERIPHERAL","year":"1952","unstructured":"ANDRADE C, A PECULIAR FORM OF PERIPHERAL, NEUROPATHY: FAMILIAR ATYPICAL GENERALIZED AMYLOIDOSIS WITH SPECIAL INVOLVEMENT OF THE PERIPHERAL NERVES (1952) Brain 75(3):408\u2013427. https:\/\/doi.org\/10.1093\/brain\/75.3.408","journal-title":"Brain"},{"issue":"3","key":"10666_CR19","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/j.1755-3768.1968.tb02827.x","volume":"46","author":"R Andersson","year":"1968","unstructured":"Andersson R, Kassman T (1968) Vitreous Opacities in Primary Familial Amyloidosis. Acta Ophthalmol (Copenh) 46(3):441\u2013447. https:\/\/doi.org\/10.1111\/j.1755-3768.1968.tb02827.x","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"6","key":"10666_CR20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.5555\/uri:pii:0022214381900767","volume":"98","author":"S Tawara","year":"1981","unstructured":"Tawara S, Araki S, Toshimori K, Nakagawa H, Ohtaki S (1981) Amyloid fibril protein in type I familial amyloidotic polyneuropathy in Japanese. J Lab Clin Med 98(6):811\u2013822. https:\/\/doi.org\/10.5555\/uri:pii:0022214381900767","journal-title":"J Lab Clin Med"},{"issue":"9","key":"10666_CR21","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1073\/pnas.75.9.4499","volume":"75","author":"PP Costa","year":"1978","unstructured":"Costa PP, Figueira AS, Bravo FR (1978) Amyloid fibril protein related to prealbumin in familial amyloidotic polyneuropathy. Proc Natl Acad Sci U S A 75(9):4499\u20134503. https:\/\/doi.org\/10.1073\/pnas.75.9.4499","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10666_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10741-024-10444-4","volume":"30","author":"AA Girard","year":"2025","unstructured":"Girard AA, Sperry BW (2025) Contextualizing the results of HELIOS-B in the broader landscape of clinical trials for the treatment of transthyretin cardiac amyloidosis. Heart Fail Rev 30(1):69\u201373. https:\/\/doi.org\/10.1007\/s10741-024-10444-4","journal-title":"Heart Fail Rev"},{"issue":"6","key":"10666_CR23","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.tcm.2025.03.002","volume":"35","author":"AA Girard","year":"2025","unstructured":"Girard AA, Asif T, Sperry BW (2025) Advances in the screening, diagnosis, and treatment of transthyretin amyloid cardiomyopathy: New insights and future directions. Trends Cardiovasc Med 35(6):354\u2013362. https:\/\/doi.org\/10.1016\/j.tcm.2025.03.002","journal-title":"Trends Cardiovasc Med"},{"issue":"1","key":"10666_CR24","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1172\/JCI111390","volume":"74","author":"MJ Saraiva","year":"1984","unstructured":"Saraiva MJ, Birken S, Costa PP, Goodman DS (1984) Amyloid fibril protein in familial amyloidotic polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 74(1):104\u2013119. https:\/\/doi.org\/10.1172\/JCI111390","journal-title":"J Clin Invest"},{"issue":"3","key":"10666_CR25","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/s0006-291x(83)80224-1","volume":"116","author":"S Tawara","year":"1983","unstructured":"Tawara S, Nakazato M, Kangawa K, Matsuo H, Araki S (1983) Identification of amyloid prealbumin variant in familial amyloidotic polyneuropathy (Japanese type). Biochem Biophys Res Commun 116(3):880\u2013888. https:\/\/doi.org\/10.1016\/s0006-291x(83)80224-1","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10666_CR26","first-page":"391","volume":"117","author":"P Pitk\u00e4nen","year":"1984","unstructured":"Pitk\u00e4nen P, Westermark P, Cornwell GG (1984) Senile systemic amyloidosis. Am J Pathol 117(3):391\u2013399","journal-title":"Am J Pathol"},{"issue":"7","key":"10666_CR27","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1073\/pnas.87.7.2843","volume":"87","author":"P Westermark","year":"1990","unstructured":"Westermark P, Sletten K, Johansson B, Cornwell GG (1990) Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci 87(7):2843\u20132845. https:\/\/doi.org\/10.1073\/pnas.87.7.2843","journal-title":"Proc Natl Acad Sci"},{"key":"10666_CR28","doi-asserted-by":"publisher","first-page":"102469","DOI":"10.1016\/j.nuclcard.2025.102469","volume":"51","author":"BW Sperry","year":"2025","unstructured":"Sperry BW, Jaber WA (2025) The Perugini grades after 20 years: Time for a modern framework. J Nucl Cardiol 51:102469. https:\/\/doi.org\/10.1016\/j.nuclcard.2025.102469","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"10666_CR29","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1161\/01.CIR.50.3.540","volume":"50","author":"RW PARKEY","year":"1974","unstructured":"PARKEY RW, BONTE FJ, MEYER SL et al (1974) A New Method for Radionuclide Imaging of Acute Myocardial Infarction in Humans. Circulation 50(3):540\u2013546. https:\/\/doi.org\/10.1161\/01.CIR.50.3.540","journal-title":"Circulation"},{"issue":"4, Part 1","key":"10666_CR30","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/0002-8703(82)90331-3","volume":"103","author":"TA Wizenberg","year":"1982","unstructured":"Wizenberg TA, Muz J, Sohn YH, Samlowski W, Weissler AM (1982) Value of positive myocardial technetium-99m-pyrophosphate scintigraphy in the noninvasive diagnosis of cardiac amyloidosis. Am Heart J 103(4, Part 1):468\u2013473. https:\/\/doi.org\/10.1016\/0002-8703(82)90331-3","journal-title":"Am Heart J"},{"issue":"4, Part 1","key":"10666_CR31","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/0002-8703(82)90343-X","volume":"103","author":"S Schiff","year":"1982","unstructured":"Schiff S, Bateman T, Moffatt R, Davidson R, Berman D (1982) Diagnostic considerations in cardiomyopathy: Unique scintigraphic pattern of diffuse biventricular technetium-99m-pyrophosphate uptake in amyloid heart disease. Am Heart J 103(4, Part 1):562\u2013563. https:\/\/doi.org\/10.1016\/0002-8703(82)90343-X","journal-title":"Am Heart J"},{"issue":"4, Part 1","key":"10666_CR32","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/0002-8703(82)90344-1","volume":"103","author":"SM Sobol","year":"1982","unstructured":"Sobol SM, Brown JM, Bunker SR, Patel J, Lull RJ (1982) Noninvasive diagnosis of cardiac amyloidosis by technetium-99m-pyrophosphate myocardial scintigraphy. Am Heart J 103(4, Part 1):563\u2013566. https:\/\/doi.org\/10.1016\/0002-8703(82)90344-1","journal-title":"Am Heart J"},{"key":"10666_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijcard.2022.01.036","volume":"352","author":"U Thelander","year":"2022","unstructured":"Thelander U, Westermark GT, Antoni G et al (2022) Cardiac microcalcifications in transthyretin (ATTR) amyloidosis. Int J Cardiol 352:84\u201391. https:\/\/doi.org\/10.1016\/j.ijcard.2022.01.036","journal-title":"Int J Cardiol"},{"issue":"6","key":"10666_CR34","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F et al (2005) Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99mTc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid Scintigraphy. J Am Coll Cardiol 46(6):1076\u20131084. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073","journal-title":"J Am Coll Cardiol"},{"key":"10666_CR35","doi-asserted-by":"crossref","unstructured":"Sperry BW Quantitative Changes Between 1 and 3 hours in Technetium Pyrophosphate Cardiac Amyloid SPECT Imaging. JNC. Published online 2025.","DOI":"10.1016\/j.nuclcard.2025.102568"},{"issue":"1","key":"10666_CR36","doi-asserted-by":"publisher","first-page":"e019375","DOI":"10.1161\/CIRCIMAGING.125.019375","volume":"19","author":"BW Sperry","year":"2026","unstructured":"Sperry BW, Miller RJH (2026) Imaging Time, Quantitation, and the Evolving Practice of Cardiac Amyloid Radionuclide Imaging. Circ Cardiovasc Imaging 19(1):e019375. https:\/\/doi.org\/10.1161\/CIRCIMAGING.125.019375","journal-title":"Circ Cardiovasc Imaging"},{"issue":"2","key":"10666_CR37","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10072-020-04889-2","volume":"43","author":"F Manganelli","year":"2022","unstructured":"Manganelli F, Fabrizi GM, Luigetti M, Mandich P, Mazzeo A, Pareyson D (2022) Hereditary transthyretin amyloidosis overview. Neurol Sci 43(2):595\u2013604. https:\/\/doi.org\/10.1007\/s10072-020-04889-2","journal-title":"Neurol Sci"},{"issue":"9","key":"10666_CR38","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1001\/jama.2024.0442","volume":"331","author":"FL Ruberg","year":"2024","unstructured":"Ruberg FL, Maurer MS (2024) Cardiac Amyloidosis Due to Transthyretin Protein. JAMA 331(9):778\u2013791. https:\/\/doi.org\/10.1001\/jama.2024.0442","journal-title":"JAMA"},{"key":"10666_CR39","doi-asserted-by":"publisher","unstructured":"Sperry BW, Tang WHW (2017) Amyloid heart disease: genetics translated into disease-modifying therapy. Published online June 1. https:\/\/doi.org\/10.1136\/heartjnl-2016-309914","DOI":"10.1136\/heartjnl-2016-309914"},{"issue":"3","key":"10666_CR40","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.21037\/jtd.2018.03.134","volume":"10","author":"IG Halatchev","year":"2018","unstructured":"Halatchev IG, Zheng J, Ou J (2018) Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies. J Thorac Dis 10(3):2034\u20132045. https:\/\/doi.org\/10.21037\/jtd.2018.03.134","journal-title":"J Thorac Dis"},{"issue":"Suppl 1","key":"10666_CR41","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4137\/CMC.S15719","volume":"8","author":"VK Ton","year":"2014","unstructured":"Ton VK, Mukherjee M, Judge DP (2014) Transthyretin cardiac amyloidosis: pathogenesis, treatments, and emerging role in heart failure with preserved ejection fraction. Clin Med Insights Cardiol 8(Suppl 1):39\u201344. https:\/\/doi.org\/10.4137\/CMC.S15719","journal-title":"Clin Med Insights Cardiol"},{"issue":"6","key":"10666_CR42","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","volume":"93","author":"A Carroll","year":"2022","unstructured":"Carroll A, Dyck PJ, de Carvalho M et al (2022) Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. J Neurol Neurosurg Psychiatry 93(6):668\u2013678. https:\/\/doi.org\/10.1136\/jnnp-2021-327909","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"12","key":"10666_CR43","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2169\/internalmedicine.43.1107","volume":"43","author":"Sichi Ikeda","year":"2004","unstructured":"Ikeda Sichi (2004) Cardiac Amyloidosis: Heterogenous Pathogenic Backgrounds. Intern Med 43(12):1107\u20131114. https:\/\/doi.org\/10.2169\/internalmedicine.43.1107","journal-title":"Intern Med"},{"issue":"8853","key":"10666_CR44","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/0140-6736(93)93127-M","volume":"341","author":"G Holmgren","year":"1993","unstructured":"Holmgren G, Steen L, Suhr O et al (1993) Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 341(8853):1113\u20131116. https:\/\/doi.org\/10.1016\/0140-6736(93)93127-M","journal-title":"Lancet"},{"issue":"1","key":"10666_CR45","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11886-024-02172-w","volume":"27","author":"AGM Patel","year":"2025","unstructured":"Patel AGM, Li P, Badrish N, Kesari A, Shah KB (2025) Transthyretin Cardiac Amyloidosis: Current and Emerging Therapies. Curr Cardiol Rep 27(1):33. https:\/\/doi.org\/10.1007\/s11886-024-02172-w","journal-title":"Curr Cardiol Rep"},{"issue":"5","key":"10666_CR46","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.jcmg.2024.11.003","volume":"18","author":"S Dorbala","year":"2025","unstructured":"Dorbala S, Adigun R, Alexander KM et al (2025) Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis. JACC Cardiovasc Imaging 18(5):602\u2013617. https:\/\/doi.org\/10.1016\/j.jcmg.2024.11.003","journal-title":"JACC Cardiovasc Imaging"},{"key":"10666_CR47","doi-asserted-by":"publisher","first-page":"384","DOI":"10.18632\/oncotarget.28415","volume":"14","author":"M Bou Zerdan","year":"2023","unstructured":"Bou Zerdan M, Nasr L, Khalid F et al (2023) Systemic AL amyloidosis: current approach and future direction. Oncotarget 14:384\u2013394. https:\/\/doi.org\/10.18632\/oncotarget.28415","journal-title":"Oncotarget"},{"issue":"25","key":"10666_CR48","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1016\/j.jacc.2016.03.593","volume":"67","author":"BW Sperry","year":"2016","unstructured":"Sperry BW, Ikram A, Hachamovitch R et al (2016) Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure. J Am Coll Cardiol 67(25):2941\u20132948. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.593","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10666_CR49","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","volume":"385","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Palladini G, Minnema MC et al (2021) Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med 385(1):46\u201358. https:\/\/doi.org\/10.1056\/NEJMoa2028631","journal-title":"N Engl J Med"},{"issue":"4","key":"10666_CR50","doi-asserted-by":"publisher","first-page":"147","DOI":"10.14740\/jh866","volume":"10","author":"M Elsayed","year":"2021","unstructured":"Elsayed M, Usher S, Habib MH et al (2021) Current Updates on the Management of AL Amyloidosis. J Hematol 10(4):147\u2013161. https:\/\/doi.org\/10.14740\/jh866","journal-title":"J Hematol"},{"issue":"1","key":"10666_CR51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.5527\/wjn.v5.i1.66","volume":"5","author":"R Scarpioni","year":"2016","unstructured":"Scarpioni R, Ricardi M, Albertazzi V (2016) Secondary amyloidosis in autoinflammatory diseases and the role of inflammation in renal damage. World J Nephrol 5(1):66\u201375. https:\/\/doi.org\/10.5527\/wjn.v5.i1.66","journal-title":"World J Nephrol"},{"key":"10666_CR52","doi-asserted-by":"publisher","unstructured":"Natural History and Outcome in Systemic AA Amyloidosis | NEJM. The New England Journal of Medicine. Accessed April 3 (2026) https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa070265","DOI":"10.1056\/NEJMoa070265"},{"issue":"2","key":"10666_CR53","doi-asserted-by":"publisher","first-page":"e72055","DOI":"10.1002\/ccr3.72055","volume":"14","author":"AS Matarneh","year":"2026","unstructured":"Matarneh AS, Matarneh B, Salameh OK et al (2026) Leukocyte Chemotactic Factor 2 Amyloidosis (LECT-2) Amyloidosis Case Report and Review of the Current Literature. Clin Case Rep 14(2):e72055. https:\/\/doi.org\/10.1002\/ccr3.72055","journal-title":"Clin Case Rep"},{"issue":"1","key":"10666_CR54","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s12882-026-04854-9","volume":"27","author":"L Li","year":"2026","unstructured":"Li L, Wu Y, Hu Z (2026) Concurrence of renal amyloidosis and membranous nephropathy: a case series and literature review. BMC Nephrol 27(1):210. https:\/\/doi.org\/10.1186\/s12882-026-04854-9","journal-title":"BMC Nephrol"},{"issue":"4","key":"10666_CR55","doi-asserted-by":"publisher","first-page":"168441","DOI":"10.1016\/j.jmb.2024.168441","volume":"436","author":"G Andreotti","year":"2024","unstructured":"Andreotti G, Baur J, Ugrina M et al (2024) Insights into the Structural Basis of Amyloid Resistance Provided by Cryo-EM Structures of AApoAII Amyloid Fibrils. J Mol Biol 436(4):168441. https:\/\/doi.org\/10.1016\/j.jmb.2024.168441","journal-title":"J Mol Biol"},{"key":"10666_CR56","doi-asserted-by":"publisher","first-page":"107355","DOI":"10.1016\/j.jaccas.2026.107355","volume":"14","author":"Y Masutani","year":"2026","unstructured":"Masutani Y, Onoue K, Soeda T et al (2026) Apolipoprotein A-IV Cardiac Amyloidosis Diagnosed by Mass Spectrometry\u2013Based Proteomic Analysis. JACC Case Rep. Published online March 14:107355. https:\/\/doi.org\/10.1016\/j.jaccas.2026.107355","journal-title":"Published online March"},{"issue":"4","key":"10666_CR57","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s13730-025-01003-3","volume":"14","author":"T Ito","year":"2025","unstructured":"Ito T, Kato T, Yamamoto S et al (2025) An end-stage kidney disease patient undergoing dialysis treatment for 50 years with dialysis-related amyloidosis in multiple organs. CEN Case Rep 14(4):665\u2013673. https:\/\/doi.org\/10.1007\/s13730-025-01003-3","journal-title":"CEN Case Rep"},{"issue":"3","key":"10666_CR58","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10741-025-10493-3","volume":"30","author":"A Aimo","year":"2025","unstructured":"Aimo A, Ferrari Chen YF, Castiglione V et al (2025) Positron emission tomography in cardiac amyloidosis: current evidence and future directions. Heart Fail Rev 30(3):605\u2013618. https:\/\/doi.org\/10.1007\/s10741-025-10493-3","journal-title":"Heart Fail Rev"},{"issue":"9","key":"10666_CR59","doi-asserted-by":"publisher","first-page":"100998","DOI":"10.1016\/j.jacadv.2024.100998","volume":"3","author":"A Vrudhula","year":"2024","unstructured":"Vrudhula A, Stern L, Cheng PC et al (2024) Impact of Case and Control Selection on Training Artificial Intelligence Screening of Cardiac Amyloidosis. JACC Adv 3(9):100998. https:\/\/doi.org\/10.1016\/j.jacadv.2024.100998","journal-title":"JACC Adv"},{"issue":"11","key":"10666_CR60","doi-asserted-by":"publisher","first-page":"102067","DOI":"10.1016\/j.jacadv.2025.102067","volume":"4","author":"G Duffy","year":"2025","unstructured":"Duffy G, Oikonomou EK, Easton N et al (2025) International Validation of Echocardiographic Artificial Intelligence Amyloid Detection Algorithm. JACC Adv 4(11):102067. https:\/\/doi.org\/10.1016\/j.jacadv.2025.102067","journal-title":"JACC Adv"},{"issue":"4","key":"10666_CR61","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/13506129.2024.2405948","volume":"31","author":"JN Buxbaum","year":"2024","unstructured":"Buxbaum JN, Eisenberg DS, F\u00e4ndrich M et al (2024) Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid 31(4):249\u2013256. https:\/\/doi.org\/10.1080\/13506129.2024.2405948","journal-title":"Amyloid"},{"issue":"1","key":"10666_CR62","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.anndiagpath.2011.10.010","volume":"16","author":"MR Wick","year":"2012","unstructured":"Wick MR (2012) Histochemistry as a tool in morphological analysis: a historical review. Ann Diagn Pathol 16(1):71\u201378. https:\/\/doi.org\/10.1016\/j.anndiagpath.2011.10.010","journal-title":"Ann Diagn Pathol"},{"key":"10666_CR63","unstructured":"Cai C (2026) Amyloid neuropathy. Pathology Outlines. Accessed April 3. https:\/\/www.pathologyoutlines.com\/topic\/muscleamyloid.html"},{"issue":"1","key":"10666_CR64","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1196\/annals.1363.025","volume":"1066","author":"W Guo","year":"2006","unstructured":"Guo W, Shea JE, Berry RS (2006) The Physics of the Interactions Governing Folding and Association of Proteins. Ann N Y Acad Sci 1066(1):34\u201353. https:\/\/doi.org\/10.1196\/annals.1363.025","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10666_CR65","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41540-025-00582-2","volume":"11","author":"U Lomoio","year":"2025","unstructured":"Lomoio U, Carbonari V, Giorgi FM et al (2025) Integrative structural profiling and ligand optimisation across the transthyretin mutational landscape. Npj Syst Biol Appl 11(1):104. https:\/\/doi.org\/10.1038\/s41540-025-00582-2","journal-title":"Npj Syst Biol Appl"},{"issue":"6, Part B","key":"10666_CR66","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1016\/j.bbadis.2017.12.009","volume":"1864","author":"J Zhao","year":"2018","unstructured":"Zhao J, Zhang B, Zhu J, Nussinov R, Ma B (2018) Structure and energetic basis of overrepresented \u03bb light chain in systemic light chain amyloidosis patients. Biochim Biophys Acta BBA - Mol Basis Dis 1864(6, Part B):2294\u20132303. https:\/\/doi.org\/10.1016\/j.bbadis.2017.12.009","journal-title":"Biochim Biophys Acta BBA - Mol Basis Dis"},{"issue":"6","key":"10666_CR67","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1021\/acs.jpcb.9b10843","volume":"124","author":"W Wang","year":"2020","unstructured":"Wang W, Khatua P, Hansmann UHE (2020) Cleavage, Downregulation, and Aggregation of Serum Amyloid A. J Phys Chem B 124(6):1009\u20131019. https:\/\/doi.org\/10.1021\/acs.jpcb.9b10843","journal-title":"J Phys Chem B"},{"issue":"16","key":"10666_CR68","doi-asserted-by":"publisher","first-page":"7908","DOI":"10.3390\/ijms26167908","volume":"26","author":"HE Rajha","year":"2025","unstructured":"Rajha HE, Hassanein A, Mesilhy R et al (2025) Apolipoprotein A (ApoA) in Neurological Disorders: Connections and Insights. Int J Mol Sci 26(16):7908. https:\/\/doi.org\/10.3390\/ijms26167908","journal-title":"Int J Mol Sci"},{"issue":"33","key":"10666_CR69","doi-asserted-by":"publisher","first-page":"17133","DOI":"10.1074\/jbc.M116.720375","volume":"291","author":"H Zheng","year":"2016","unstructured":"Zheng H, Miyakawa T, Sawano Y et al (2016) Crystal Structure of Human Leukocyte Cell-derived Chemotaxin 2 (LECT2) Reveals a Mechanistic Basis of Functional Evolution in a Mammalian Protein with an M23 Metalloendopeptidase Fold*. J Biol Chem 291(33):17133\u201317142. https:\/\/doi.org\/10.1074\/jbc.M116.720375","journal-title":"J Biol Chem"},{"issue":"1","key":"10666_CR70","doi-asserted-by":"publisher","first-page":"4517","DOI":"10.1038\/s41467-018-06761-6","volume":"9","author":"MG Iadanza","year":"2018","unstructured":"Iadanza MG, Silvers R, Boardman J et al (2018) The structure of a \u03b22-microglobulin fibril suggests a molecular basis for its amyloid polymorphism. Nat Commun 9(1):4517. https:\/\/doi.org\/10.1038\/s41467-018-06761-6","journal-title":"Nat Commun"},{"key":"10666_CR71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21217830","volume":"21","author":"R Asselta","year":"2020","unstructured":"Asselta R, Paraboschi E, Duga S (2020) Hereditary Hypofibrinogenemia with Hepatic Storage. Int J Mol Sci 21:1\u201317. https:\/\/doi.org\/10.3390\/ijms21217830","journal-title":"Int J Mol Sci"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10666-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-026-10666-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-026-10666-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:08:47Z","timestamp":1787717327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-026-10666-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10666"],"URL":"https:\/\/doi.org\/10.1007\/s10741-026-10666-8","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"assertion":[{"value":"11 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BWS has received professional fees from AstraZeneca, Alnylam, AstraZeneca, BridgeBio, and Pfizer.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BWS has received professional fees from AstraZeneca, Alnylam, AstraZeneca, BridgeBio, and Pfizer.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"96"}}